Human Antimicrobial Susceptibility Testing Market by Type, Product, Method, Application, End User

Description

List of Tables

[180 Pages Report] The Human Antimicrobial Susceptibility Testing Market size was estimated at USD 3.71 billion in 2023 and expected to reach USD 3.92 billion in 2024, at a CAGR 5.88% to reach USD 5.54 billion by 2030.

The human antimicrobial susceptibility testing (AST) market encompasses the range of diagnostic processes and products employed to determine the susceptibility of specific microbial organisms, including bacteria and fungi, to various antimicrobial agents. This testing is crucial in guiding the appropriate selection of antimicrobial therapy for individual patients, optimizing clinical outcomes, and mitigating the risk of resistance development. The rising prevalence of bacterial and fungal infections globally fuels the demand for effective diagnostic testing such as AST. The growing problem of resistance to existing antibiotics underscores the need for AST to tailor treatments and develop new antimicrobials. However, the cost and complexity of advanced AST systems may limit accessibility, particularly in low-resource settings. Moreover, rising healthcare infrastructure and increasing awareness about infectious diseases in regions present significant growth opportunities. Development of portable, easy-to-use AST systems for use in outpatient settings or remote areas. Along with these, employing AI to predict susceptibility and resistance patterns could streamline AST processes, enhance predictive accuracy, and create new growth opportunities for the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.71 billion
Estimated Year [2024]	USD 3.92 billion
Forecast Year [2030]	USD 5.54 billion
CAGR (%)	5.88%

Regional Insights

In the Americas, the United States holds a significant portion of the market due to its well-established healthcare infrastructure and high awareness regarding AMR. The region strongly emphasizes research and development, leading to the adoption of advanced AST technologies such as automated systems and genotypic methods. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) play a crucial role in approving and overseeing AST products, ensuring their efficacy and safety. The EMEA region presents a diverse AST market due to varying levels of economic development, healthcare infrastructure, and regulatory frameworks. Europe is among the significant areas of adopting advanced AST methods, supported by strong regulatory standards set by the European Medicines Agency (EMA) and national bodies. The region is also at the forefront of addressing AMR through comprehensive antimicrobial stewardship programs. The Middle East shows a growing demand for AST due to rising AMR awareness and healthcare investments, particularly in Gulf Cooperation Council (GCC) countries. APAC is witnessing rapid growth in the AST market, fueled by increasing healthcare expenditures and rising awareness of AMR in countries such as China and India. The region benefits from local manufacturing of AST products, reducing costs and enhancing access. However, the vast diversity in economic and healthcare development levels across the region results in varied adoption rates of AST technologies.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Human Antimicrobial Susceptibility Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of infectious diseases due to the rising pathogens
- Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
- Surging use of antimicrobial susceptibility testing by biopharmaceutical companies

Market Restraints
- High cost of automated antimicrobial susceptibility testing

Market Opportunities
- Technological advancements towards the development of rapid human AST methods
- Increasing funding, research grants, and public-private investments in the market

Market Challenges
- Complex regulatory frameworks coupled with issues in testing in developing countries

Market Segmentation Analysis
- Type: Rising R&D investment to develop next generation susceptibility testing
- End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Human Antimicrobial Susceptibility Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Human Antimicrobial Susceptibility Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management

CARB-X, an entity in the biopharmaceutical sector dedicated to combating antibiotic resistance, has allocated up to USD 1.8 million in funding to Visby Medical. This significant financial commitment supports the development of an innovative, portable, rapid polymerase chain reaction (PCR) diagnostic tool. This tool is designed to accurately identify the presence of Neisseria gonorrhoeae (NG), the pathogen responsible for gonorrhea, and ascertain its susceptibility to ciprofloxacin. [Published On: 2024-02-08]

Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance

Microplate Dx, a Glasgow-based diagnostics innovator, has successfully secured GBP 2.5 million in seed funding to propel the development of a point-of-care device designed for the rapid identification of effective antibiotics against bacterial infections. This funding initiative is poised to support clinical trials in Europe, with ambitions to expand into the US market. In alignment with the World Health Organization's concerns over rising antimicrobial resistance and supported by the UK's significant investment to combat antibiotic-resistant bacteria globally, Microplate Dx's technology aims to revolutionize antibiotic susceptibility testing. [Published On: 2023-09-11]

Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System

Sysmex Corporation has introduced a new antimicrobial susceptibility testing (AST) system in Europe aimed to transform the approach to diagnosing and treating urinary tract infections (UTIs). Leveraging advanced microfluidic technology developed by its subsidiary, Sysmex Astrego, the system delivers rapid detection of bacterial presence in urine samples and evaluates the efficacy of antimicrobials in as little as 30 minutes. This novel testing system comprises a compact analyzer and user-friendly sample cartridges, facilitating swift AST results during initial patient consultations in primary care and other outpatient settings. [Published On: 2023-06-26]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Human Antimicrobial Susceptibility Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Human Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIBBI MALZ, BioMerieux SA, Biosafe Ltd., Bruker Corporation, Creative Diagnostics, ELITech Group SAS, Erba Lachema s.r.o., F. Hoffmann-La Roche AG, Genefluidics, Inc., Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Liofilchem S.r.l., Mast Group Ltd., Merck KGaA, Pfizer Inc., Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Antimicrobial Susceptibility Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Antibacterial Susceptibility Testing
- Antifungal Susceptibility Testing
- Antiparasitic Susceptibility Testing

Product
- Automated Laboratory Instruments
- Consumables
- Culture & Growth Media
- Manual Antimicrobial Susceptibility Testing Products

Method
- Agar Dilution
- Automated Susceptibility Testing Instruments
- Disk Diffusion
- Etest Method
- Genotyping Methods

Application
- Clinical Diagnostics
- Drug Discovery & Development
- Epidemiology

End User
- Contract Research Organizations
- Hospital & Diagnostic Centers
- Pharmaceutical & Biotechnology
- Research & Academic Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-4E27A4DF1227

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of infectious diseases due to the rising pathogens
  - 5.1.1.2. Rising government initiatives to create awareness of antimicrobial resistance and curb antimicrobial abuse
  - 5.1.1.3. Surging use of antimicrobial susceptibility testing by biopharmaceutical companies
- 5.1.2. Restraints
  - 5.1.2.1. High cost of automated antimicrobial susceptibility testing
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements towards the development of rapid human AST methods
  - 5.1.3.2. Increasing funding, research grants, and public-private investments in the market
- 5.1.4. Challenges
  - 5.1.4.1. Complex regulatory frameworks coupled with issues in testing in developing countries
5.2. Market Segmentation Analysis
- 5.2.1. Type: Rising R&D investment to develop next generation susceptibility testing
- 5.2.2. End User: Rising demand across hospital & diagnostic centers to guide patient-specific treatment strategies
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Human Antimicrobial Susceptibility Testing Market, by Type

6.1. Introduction
6.2. Antibacterial Susceptibility Testing
6.3. Antifungal Susceptibility Testing
6.4. Antiparasitic Susceptibility Testing

7. Human Antimicrobial Susceptibility Testing Market, by Product

7.1. Introduction
7.2. Automated Laboratory Instruments
7.3. Consumables
7.4. Culture & Growth Media
7.5. Manual Antimicrobial Susceptibility Testing Products

8. Human Antimicrobial Susceptibility Testing Market, by Method

8.1. Introduction
8.2. Agar Dilution
8.3. Automated Susceptibility Testing Instruments
8.4. Disk Diffusion
8.5. Etest Method
8.6. Genotyping Methods

9. Human Antimicrobial Susceptibility Testing Market, by Application

9.1. Introduction
9.2. Clinical Diagnostics
9.3. Drug Discovery & Development
9.4. Epidemiology

10. Human Antimicrobial Susceptibility Testing Market, by End User

10.1. Introduction
10.2. Contract Research Organizations
10.3. Hospital & Diagnostic Centers
10.4. Pharmaceutical & Biotechnology
10.5. Research & Academic Institutes

11. Americas Human Antimicrobial Susceptibility Testing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Human Antimicrobial Susceptibility Testing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Human Antimicrobial Susceptibility Testing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Strategic Investment in Rapid Diagnostic Technologies by CARB-X to Combat Antibiotic-Resistant Gonorrhea and Enhance Global STI Management
- 14.3.2. Microplate Secures Funding for Innovation in Combatting Antimicrobial Resistance
- 14.3.3. Introducing Sysmex's Rapid Antimicrobial Susceptibility Testing System
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio